1887

Abstract

The ISCOMATRIX adjuvant has antigen delivery and presentation properties as well as immunomodulatory capabilities, which combine to provide enhanced and accelerated immune responses. The responses are broad, including a range of subclasses of antibodies as well as CD4 and CD8 T-cells. A range of ISCOMATRIX vaccines (ISCOMATRIX adjuvant combined with antigen) have now been tested in clinical trials and have been shown to be generally safe and well tolerated as well as immunogenic, generating both antibody (Ab) and T-cell responses. The mechanisms by which ISCOMATRIX adjuvant facilitates its immune effects are the scope of significant study and indicate that ISCOMATRIX adjuvant (i) rapidly traffics antigen into the cytosol of multiple dendritic cell subsets, (ii) induces the induction of an array of cytokines and chemokines and (iii) links the innate and adaptive immune responses in a Toll-like-receptor-independent but MyD88-dependent manner. These data highlight the clinical utility of ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines for infectious disease.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.040857-0
2012-07-01
2022-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/7/935.html?itemId=/content/journal/jmm/10.1099/jmm.0.040857-0&mimeType=html&fmt=ahah

References

  1. Agnandji S. T., Lell B., Soulanoudjingar S. S., Fernandes J. F., Abossolo B. P., Conzelmann C., Methogo B. G., Doucka Y., Flamen A. other authors 2011; First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365:1863–1875 [View Article][PubMed]
    [Google Scholar]
  2. Anderson J. S., Hoy J., Hillman R., Barnden M., Eu B., McKenzie A., Gittleson C. 2009; A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr 52:371–381 [View Article][PubMed]
    [Google Scholar]
  3. Aurisicchio L., Ciliberto G. 2010; Patented cancer vaccines: the promising leads. Expert Opin Ther Pat 20:647–660 [View Article][PubMed]
    [Google Scholar]
  4. Banzhoff A., Gasparini R., Laghi-Pasini F., Staniscia T., Durando P., Montomoli E., Capecchi P. L., di Giovanni P., Sticchi L. other authors 2009; MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4:e4384 [View Article][PubMed]
    [Google Scholar]
  5. Beran J., Dedek P., Stepánová V., Spliio M., Pozler O. 2005; Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis. Cent Eur J Public Health 13:20–23[PubMed]
    [Google Scholar]
  6. Birmingham C. L., Canadien V., Kaniuk N. A., Steinberg B. E., Higgins D. E., Brumell J. H. 2008; Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 451:350–354 [View Article][PubMed]
    [Google Scholar]
  7. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D. M. 2011; CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 10:499–511 [View Article][PubMed]
    [Google Scholar]
  8. Boyle J., Eastman D., Millar C., Camuglia S., Cox J., Pearse M., Good J., Drane D. 2007; The utility of ISCOMATRIXTM adjuvant for dose reduction of antigen for vaccines requiring antibody responses. Vaccine 25:2541–2544 [View Article][PubMed]
    [Google Scholar]
  9. Brichard V. 2005; Development of cancer vaccines with the MAGE-3 protein. Cancer Immun 5:Suppl. 116
    [Google Scholar]
  10. Campodónico V. L., Llosa N. J., Bentancor L. V., Maira-Litran T., Pier G. B. 2011; Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice. Infect Immun 79:3455–3464 [View Article][PubMed]
    [Google Scholar]
  11. Clements D. E., Coller B. A., Lieberman M. M., Ogata S., Wang G., Harada K. E., Putnak J. R., Ivy J. M., McDonell M. other authors 2010; Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705–2715 [View Article][PubMed]
    [Google Scholar]
  12. Cooper C. L., Davis H. L., Morris M. L., Efler S. M., Adhami M. A., Krieg A. M., Cameron D. W., Heathcote J. 2004; CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693–701 [View Article][PubMed]
    [Google Scholar]
  13. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., Sutton P., Rockman S., Pearse M. 2003; Intranasal vaccination with ISCOMATRIX® adjuvanted influenza vaccine. Vaccine 21:946–949 [View Article][PubMed]
    [Google Scholar]
  14. Davis I. D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., Chen Q., Dimopoulos N., Luke T. other authors 2004; Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A 101:10697–10702 [View Article][PubMed]
    [Google Scholar]
  15. Dorn B. R., Dunn W. A. Jr, Progulske-Fox A. 2001; Porphyromonas gingivalis traffics to autophagosomes in human coronary artery endothelial cells. Infect Immun 69:5698–5708 [View Article][PubMed]
    [Google Scholar]
  16. Drane D., Gittleson C., Boyle J., Maraskovsky E. 2007; ISCOMATRIXTM adjuvant for prophylactic and therapeutic vaccines. Expert Rev Vaccines 6:761–772 [View Article][PubMed]
    [Google Scholar]
  17. Drane D., Maraskovsky E., Gibson R., Mitchell S., Barnden M., Moskwa A., Shaw D., Gervase B., Coates S. other authors 2009; Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIXTM vaccine: a phase I study in healthy volunteers. Hum Vaccin 5:151–157 [View Article][PubMed]
    [Google Scholar]
  18. Du J., Wu Z., Ren S., Wei Y., Gao M., Randolph G. J., Qu C. 2010; TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28:6273–6281 [View Article][PubMed]
    [Google Scholar]
  19. Duewell P., Kisser U., Heckelsmiller K., Hoves S., Stoitzner P., Koernig S., Morelli A. B., Clausen B. E., Dauer M. other authors 2011; ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 187:55–63 [View Article][PubMed]
    [Google Scholar]
  20. Ebert L. M., Liu Y. C., Clements C. S., Robson N. C., Jackson H. M., Markby J. L., Dimopoulos N., Tan B. S., Luescher I. F. other authors 2009; A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res 69:1046–1054 [View Article][PubMed]
    [Google Scholar]
  21. Frazer I. H., Quinn M., Nicklin J. L., Tan J., Perrin L. C., Ng P., O’Connor V. M., White O., Wendt N., Martin J. 2004; Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIXTM adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23:172–181 [View Article][PubMed]
    [Google Scholar]
  22. Garçon N., Van Mechelen M. 2011; Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10:471–486 [View Article][PubMed]
    [Google Scholar]
  23. Jacobs C., Duewell P., Heckelsmiller K., Wei J., Bauernfeind F., Ellermeier J., Kisser U., Bauer C. A., Dauer M. other authors 2011; An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer 128:897–907 [View Article][PubMed]
    [Google Scholar]
  24. Jasani B., Navabi H., Adams M. 2009; Ampligen: a potential Toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27:3401–3404 [View Article][PubMed]
    [Google Scholar]
  25. Kawai T., Akira S. 2010; The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11:373–384 [View Article][PubMed]
    [Google Scholar]
  26. Klinman D. M., Klaschik S., Sato T., Tross D. 2009; CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 61:248–255 [View Article][PubMed]
    [Google Scholar]
  27. Kool M., Pétrilli V., De Smedt T., Rolaz A., Hammad H., van Nimwegen M., Bergen I. M., Castillo R., Lambrecht B. N., Tschopp J. 2008; Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 181:3755–3759[PubMed] [CrossRef]
    [Google Scholar]
  28. Korn T., Bettelli E., Oukka M., Kuchroo V. K. 2009; IL-17 and Th17 cells. Annu Rev Immunol 27:485–517 [View Article][PubMed]
    [Google Scholar]
  29. Kuroda E., Ishii K. J., Uematsu S., Ohata K., Coban C., Akira S., Aritake K., Urade Y., Morimoto Y. 2011; Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 34:514–526 [View Article][PubMed]
    [Google Scholar]
  30. Kwissa M., Amara R. R., Robinson H. L., Moss B., Alkan S., Jabbar A., Villinger F., Pulendran B. 2007; Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204:2733–2746 [View Article][PubMed]
    [Google Scholar]
  31. Lapaque N., Moriyon I., Moreno E., Gorvel J. P. 2005; Brucella lipopolysaccharide acts as a virulence factor. Curr Opin Microbiol 8:60–66 [View Article][PubMed]
    [Google Scholar]
  32. Leroux-Roels G. 2010; Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28:Suppl. 3C25–C36 [View Article][PubMed]
    [Google Scholar]
  33. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., Devaster J. M., Leroux-Roels G. 2007; Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580–589 [View Article][PubMed]
    [Google Scholar]
  34. Li K., Foy E., Ferreon J. C., Nakamura M., Ferreon A. C., Ikeda M., Ray S. C., Gale M. Jr, Lemon S. M. 2005; Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102:2992–2997 [View Article][PubMed]
    [Google Scholar]
  35. Li S., Floess S., Hamann A., Gaudieri S., Lucas A., Hellard M., Roberts S., Paukovic G., Plebanski M. other authors 2009; Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 5:e1000707 [View Article][PubMed]
    [Google Scholar]
  36. Li Y., Hu Y., Jin Y., Zhang G., Wong J., Sun L. Q., Wang M. 2011; Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection. J Gene Med 13:60–72 [View Article][PubMed]
    [Google Scholar]
  37. Maraskovsky E., Sjölander S., Drane D. P., Schnurr M., Le T. T., Mateo L., Luft T., Masterman K. A., Tai T. Y. other authors 2004; NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 10:2879–2890 [View Article][PubMed]
    [Google Scholar]
  38. McKenzie A., Watt M., Gittleson C. 2010; ISCOMATRIXTM vaccines: safety in human clinical studies. Hum Vaccin 6:237–246 [View Article]
    [Google Scholar]
  39. Mischo A., Bubel N., Cebon J. S., Samaras P., Petrausch U., Stenner-Liewen F., Schaefer N. G., Kubuschok B., Renner C., Wadle A. 2011; Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis. Int J Oncol 39:287–294[PubMed]
    [Google Scholar]
  40. Mizel S. B., Bates J. T. 2010; Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677–5682 [View Article][PubMed]
    [Google Scholar]
  41. Morein B., Sundquist B., Höglund S., Dalsgaard K., Osterhaus A. 1984; Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457–460 [View Article][PubMed]
    [Google Scholar]
  42. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., O’Hagan D., Rappuoli R., De Gregorio E. 2008; Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 105:10501–10506 [View Article][PubMed]
    [Google Scholar]
  43. Nicholaou T., Chen W., Davis I. D., Jackson H. M., Dimopoulos N., Barrow C., Browning J., Macgregor D., Williams D. other authors 2011; Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIXTM . Cancer Immunol Immunother 60:1625–1637 [View Article][PubMed]
    [Google Scholar]
  44. O’Hagan D. T., Rappuoli R., De Gregorio E., Tsai T., Del Giudice G. 2011; MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 10:447–462 [CrossRef]
    [Google Scholar]
  45. Paavonen J., Naud P., Salmerón J., Wheeler C. M., Chow S. N., Apter D., Kitchener H., Castellsague X., Teixeira J. C. other authors 2009; Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301–314 [View Article][PubMed]
    [Google Scholar]
  46. Park J. M., Greten F. R., Li Z. W., Karin M. 2002; Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297:2048–2051 [View Article][PubMed]
    [Google Scholar]
  47. Pearse M. J., Drane D. 2004; ISCOMATRIXTM adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 22:2391–2395 [View Article][PubMed]
    [Google Scholar]
  48. Pearse M. J., Drane D. 2007; ISCOMATRIX® adjuvant for antigen delivery. Adv Drug Deliv Rev 57:465–474 [CrossRef]
    [Google Scholar]
  49. Pichlmair A., Schulz O., Tan C. P., Näslund T. I., Liljeström P., Weber F., Reis e Sousa C. 2006; RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 314:997–1001 [View Article][PubMed]
    [Google Scholar]
  50. Podda A. 2001; The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19:2673–2680 [View Article][PubMed]
    [Google Scholar]
  51. Polakos N. K., Drane D., Cox J., Ng P., Selby M. J., Chien D., O’Hagan D. T., Houghton M., Paliard X. 2001; Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 166:3589–3598[PubMed] [CrossRef]
    [Google Scholar]
  52. Robson N. C., Beacock-Sharp H., Donachie A. M., Mowat A. M. 2003; Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology 109:374–383 [View Article][PubMed]
    [Google Scholar]
  53. Sanders M. T., Deliyannis G., Pearse M. J., McNamara M. K., Brown L. E. 2009; Single dose intranasal immunization with ISCOMATRIXTM vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine 27:2475–2482 [View Article][PubMed]
    [Google Scholar]
  54. Schnurr M., Orban M., Robson N. C., Shin A., Braley H., Airey D., Cebon J., Maraskovsky E., Endres S. 2009; ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol 182:1253–1259 [View Article][PubMed]
    [Google Scholar]
  55. Seubert A., Monaci E., Pizza M., O’Hagan D. T., Wack A. 2008; The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180:5402–5412[PubMed] [CrossRef]
    [Google Scholar]
  56. Sharp F. A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., Singh M., O’Hagan D. T., Pétrilli V. other authors 2009; Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 106:870–875 [View Article][PubMed]
    [Google Scholar]
  57. Sjölander A., van ’t Land B., Lövgren Bengtsson K. 1997; Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol 177:69–76 [View Article][PubMed]
    [Google Scholar]
  58. Skene C. D., Doidge C., Sutton P. 2008; Evaluation of ISCOMATRIXTM and ISCOMTM vaccines for immunisation against Helicobacter pylori . Vaccine 26:3880–3884 [View Article][PubMed]
    [Google Scholar]
  59. Steinhagen F., Kinjo T., Bode C., Klinman D. M. 2011; TLR-based immune adjuvants. Vaccine 29:3341–3355 [View Article][PubMed]
    [Google Scholar]
  60. Sun P., Schwenk R., White K., Stoute J. A., Cohen J., Ballou W. R., Voss G., Kester K. E., Heppner D. G., Krzych U. 2003; Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8 + T cells producing IFN-γ. J Immunol 171:6961–6967[PubMed] [CrossRef]
    [Google Scholar]
  61. Takeuchi O., Akira S. 2010; Pattern recognition receptors and inflammation. Cell 140:805–820 [View Article][PubMed]
    [Google Scholar]
  62. Taylor D. N., Treanor J. J., Strout C., Johnson C., Fitzgerald T., Kavita U., Ozer K., Tussey L., Shaw A. 2011; Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29:4897–4902 [View Article][PubMed]
    [Google Scholar]
  63. Tewari K., Flynn B. J., Boscardin S. B., Kastenmueller K., Salazar A. M., Anderson C. A., Soundarapandian V., Ahumada A., Keler T. other authors 2010; Poly(I : C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Vaccine 28:7256–7266 [View Article][PubMed]
    [Google Scholar]
  64. Vaughan A. T., Roghanian A., Cragg M. S. 2011; B cells – masters of the immunoverse. Int J Biochem Cell Biol 43:280–285 [View Article][PubMed]
    [Google Scholar]
  65. Vujanic A., Wee J. L., Snibson K. J., Edwards S., Pearse M., Quinn C., Moloney M., Taylor S., Scheerlinck J. P., Sutton P. 2010; Combined mucosal and systemic immunity following pulmonary delivery of ISCOMATRIXTM adjuvanted recombinant antigens. Vaccine 28:2593–2597 [View Article][PubMed]
    [Google Scholar]
  66. Wilson N. S., Yang B., Morelli A. B., Koernig S., Yang A., Loeser S., Airey D., Provan L., Hass P. other authors 2011; ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol [Epub ahead of print]. doi:10.1038/icb.2011.71. Available at http://www.nature.com/icb/journal/vaop/ncurrent/pdf/icb201171a.pdf [View Article][PubMed]
    [Google Scholar]
  67. Wong J. P., Nagata L. P., Christopher M. E., Salazar A. M., Dale R. M. 2005; Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine 23:2266–2268 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.040857-0
Loading
/content/journal/jmm/10.1099/jmm.0.040857-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error